SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Recruiting · Phase 4 · NCT04647227

Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor

Research payments reported, 2025: $14,000
U.S. investigators named: 5
Sites paid: 5
Planned or actual enrollment: 55

About the trial

Sponsor: American Thrombosis and Hemostasis Network (with LFB USA, Inc.)
Tested: coagulation factor VIIa [recombinant]-jncw (drug)
Dates: Started 2021-06-28; completion 2027-03-31
Results posted: Not yet

Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.

From ClinicalTrials.gov, last updated 2026-01-12. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Hema Biologics, LLC reported $14,000 in research payments for this study in 2025 (5 payments).

Products named: Sevenfact

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Vanderbilt University Medical Center, TN $3,000
Mayo Clinic $3,000
The Feinstein Institute for Medical Research $3,000
Orthopaedic Hospital $3,000
Oklahoma Center for Bleeding and Clotting $2,000

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it